Northland analyst Michael Latimore lowered the firm’s price target on DocGo (DCGO) to $6 from $8 and keeps an Outperform rating on the shares after the company reported a Q4 revenue and EBITDA miss. DocGo kept its yearly revenue guidance, but lowered EBITDA growth to 5% from 8-10% on incremental investments, notes the analyst, who adds that the company should have no more migrant care revenue exiting Q2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCGO:
- DocGo downgraded to Hold from Buy at Deutsche Bank
- DocGo price target lowered to $5.50 from $6.50 at Stifel
- DocGo’s Strategic Shift Towards Sustainable Growth: Analyst Recommends Buy Despite Current Challenges
- DocGo’s Strategic Shift and Growth Potential Justify Buy Rating Despite Short-Term Challenges
- Optimistic Buy Rating for DocGo Amid Strategic Transition and Growth Potential